share_log

424B3: Prospectus

424B3: Prospectus

424B3:募資說明書
美股sec公告 ·  06/27 08:22
Moomoo AI 已提取核心訊息
NeuroSense Therapeutics has filed a prospectus supplement on June 27, 2024, to update and amend its previous prospectus dated May 22, 2024. This supplement includes information from the company's Report on Form 6-K submitted to the SEC on the same date. The supplement details amendments to warrants issued to an institutional investor, extending the termination date of warrants from 2023 and 2024 to October 12, 2029. The amendments also adjust the 'Redemption Right' in the 2023 Warrant. NeuroSense Therapeutics' ordinary shares and warrants are traded on the Nasdaq under the symbols 'NRSN' and 'NRSNW,' with closing prices on June 26, 2024, at $0.85 and $0.18 respectively. The company highlights the high degree of risk involved in investing in its securities and refers to the 'Risk Factors' section of the Prospectus for more details. The SEC, Israeli Securities Authority, nor any state securities commission has approved or disapproved the securities, nor have they confirmed the completeness or truthfulness of the Prospectus or this supplement.
NeuroSense Therapeutics has filed a prospectus supplement on June 27, 2024, to update and amend its previous prospectus dated May 22, 2024. This supplement includes information from the company's Report on Form 6-K submitted to the SEC on the same date. The supplement details amendments to warrants issued to an institutional investor, extending the termination date of warrants from 2023 and 2024 to October 12, 2029. The amendments also adjust the 'Redemption Right' in the 2023 Warrant. NeuroSense Therapeutics' ordinary shares and warrants are traded on the Nasdaq under the symbols 'NRSN' and 'NRSNW,' with closing prices on June 26, 2024, at $0.85 and $0.18 respectively. The company highlights the high degree of risk involved in investing in its securities and refers to the 'Risk Factors' section of the Prospectus for more details. The SEC, Israeli Securities Authority, nor any state securities commission has approved or disapproved the securities, nor have they confirmed the completeness or truthfulness of the Prospectus or this supplement.
NeuroSense Therapeutics於2024年6月27日提交了招股說明書的補充,以更新和修改其前一份於2024年5月22日發佈的招股說明書。該補充材料包括公司在同一日期提交給證券交易委員會的6-K表中的信息。該補充詳情修正了發行給機構投資者的認股權證,將認股權證的到期日從2023年和2024年延長至2029年10月12日。修改也調整了2023年認股權證的“贖回權”。NeuroSense Therapeutics的普通股和認股權在納斯達克上交易,代碼分別爲“NRSN”和“NRSNW”,截至2024年6月26日收盤價分別爲0.85美元和0.18美元。公司強調投資其證券涉及高風險,並引用招股說明書的“風險因素”部分以了解更多詳情。美國證券交易委員會、以色列證券管理機構或任何州證券委員會均未批准或不批准證券,亦未證實招股說明書或本補充的完整性或真實性。
NeuroSense Therapeutics於2024年6月27日提交了招股說明書的補充,以更新和修改其前一份於2024年5月22日發佈的招股說明書。該補充材料包括公司在同一日期提交給證券交易委員會的6-K表中的信息。該補充詳情修正了發行給機構投資者的認股權證,將認股權證的到期日從2023年和2024年延長至2029年10月12日。修改也調整了2023年認股權證的“贖回權”。NeuroSense Therapeutics的普通股和認股權在納斯達克上交易,代碼分別爲“NRSN”和“NRSNW”,截至2024年6月26日收盤價分別爲0.85美元和0.18美元。公司強調投資其證券涉及高風險,並引用招股說明書的“風險因素”部分以了解更多詳情。美國證券交易委員會、以色列證券管理機構或任何州證券委員會均未批准或不批准證券,亦未證實招股說明書或本補充的完整性或真實性。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息